Preoperative skeletal muscle status is associated with tumor-infiltrating lymphocytes and prognosis in patients with colorectal cancer

Nobuya Daitoku1 | Yuji Miyamoto1 | Yukiharu Hiyoshi1 | Ryuma Tokunaga1 | Yuki Sakamoto1 | Hiroshi Sawayama1 | Takatsugu Ishimoto1,2 | Yoshifumi Baba1 | Naoya Yoshida1 | Hideo Baba1

1Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
2International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan

Correspondence
Hideo Baba, Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan.
Email: hdobaba@kumamoto-u.ac.jp

Abstract

Background: Sarcopenia is associated with poor prognosis in patients with colorectal cancer (CRC), but the mechanisms contributing to this association remain unclear. We hypothesized that skeletal muscle status is associated with tumor-infiltrating lymphocytes (TILs) in patients with CRC. Therefore, this study investigated the clinical effect of sarcopenia and its relationship with the local immune system in CRC patients.

Methods: A total of 256 consecutive patients with CRC who underwent curative resection between 2008 and 2014 were enrolled. Sarcopenia was determined according to the skeletal muscle index (SMI), which was assessed using L3 skeletal muscle mass on axial computed tomography images, and its relationship with patient clinicopathological characteristics and survival was evaluated. Additionally, TILs (CD3+, CD8+, CD4+, and FOXP3+ T cells) were assayed by immunohistochemistry. The relationship between TILs and skeletal muscle status was evaluated.

Results: Patients with a lower SMI showed significantly shorter recurrence-free and overall survival compared with those with a higher SMI. Low expression of TILs was associated with significantly shorter recurrence-free survival. SMI was significantly correlated with the number of CD3+ and CD8+ cells in the ordinal logistic regression analysis. Patients with low skeletal muscle status and low CD3+ and CD8+ cells had an unfavorable prognosis compared with patients with high skeletal muscle status and high CD3+ and CD8+ cells.

Conclusion: Our data showed an association between skeletal muscle status and local immune cells, and this association may play a pivotal role in the clinical outcome of patients with CRC.

Keywords: colorectal cancer, prognosis, sarcopenia, skeletal muscle index, tumor-infiltrating lymphocytes
INTRODUCTION

Colorectal cancer (CRC) is currently the third most common cause of cancer-related mortality in economically developed countries, and is on track to increase in ranking in the coming decades. Surgical resection with adjuvant chemotherapy offers the only hope for a cure and can promote long-term survival in CRC patients. However, CRC recurs in ~30% of patients, and better treatment options are needed to improve the prognosis. Moreover, because CRC has a high relapse rate, even after early radical resection, there is a need for additional biomarkers that can complement currently available treatments. This will help to predict early postoperative recurrence and poor prognosis in patients with CRC.

Accumulating evidence suggests that skeletal muscle mass is associated with survival outcomes in patients with various cancers. In CRC, several studies have shown that patients with low skeletal muscle mass, as measured by preoperative computed tomography (CT), have poor survival outcomes compared with those with normal skeletal muscle mass. Skeletal muscle measurement using diagnostic CT scans may improve patient management when utilized for prognostic prediction in CRC patients. However, the mechanisms underlying the influence of skeletal muscle loss on cancer prognosis remain unclear.

Tumor-infiltrating lymphocytes (TILs) are an essential histopathological feature of CRC that provides prognostic information. Previous clinical and epidemiological studies found that high levels of TILs were significantly associated with better disease-specific and overall survival of patients with CRC. In addition, a scoring system called Immunoscore, which summarizes the densities of CD3+ and CD8+ T-cell effectors within the tumor and its invasive margins, has been shown to be useful in predicting the clinical outcome of patients with CRC. High levels of TILs in CRC could also effectively predict response to chemotherapy in patients with CRC. Interestingly, patients with a higher level of TILs were more likely to benefit from chemotherapy in terms of recurrence risk. As part of the local immune system, tumor infiltration of immune cells could represent host immune reactions against cancer cell proliferation and affect prognosis in patients with CRC. More recently, reports have shown a significant correlation between TILs and sarcopenia. We previously showed that patients with sarcopenia had significantly fewer CD8+ cells than patients with extrahepatic cholangiocarcinoma.

Therefore, we hypothesized that skeletal muscle status might be associated with the number of TILs in patients with CRC. A better understanding of the relationship between patient skeletal muscle status and immune cells in the tumor microenvironment may create new opportunities for CRC treatment to target the skeletal muscle. Thus, this study aimed to investigate the role of TILs as a prognostic factor in CRC and the relationship between sarcopenia and the local immune system in CRC patients.

MATERIALS AND METHODS

2.1 Patients

We recruited 256 patients with CRC who had undergone primary tumor resection at Kumamoto University Hospital between April 2008 and December 2014. Patients with histologically verified colorectal adenocarcinoma who had undergone primary tumor resection and enhanced CT at least 1 mo prior to surgery were eligible. Additionally, only patients whose tumors were available for immunostaining of TILs were eligible. Patients who had received preoperative chemotherapy, radiotherapy, or emergent surgery were excluded. Pathological findings were prospectively evaluated according to the seventh edition of the American Joint Committee on Cancer system of CRC.

Patients were followed up at 3–6 mo intervals until death or for at least 5 y. Recurrence-free survival (RFS) was defined as the time between the surgery date and the date of recurrence or death. Overall survival (OS) was defined as the time between the surgery date and the date of death. All patients provided informed consent, including permission for tumor tissue and the use of images to explore parameters. This study was conducted according to the REporting recommendations for tumor MARKer prognostic studies (REMARK).

The tissue analysis protocol was approved by the Kumamoto University Institutional Review Board of Medical Sciences and conducted at Kumamoto University in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

2.2 Tissue samples

CRC tissue or paired normal epithelial tissue was obtained at the time of surgical resection, snap-frozen, and stored at −80°C until use. RNA or cDNA was extracted from frozen sample tissue as described below. Formalin-fixed paraffin-embedded tissue samples were used for immunohistochemical staining.

2.3 Immunohistochemistry

Paraffin-embedded tumor sections were dewaxed in xylene and ethanol and autoclaved for 15 min in an antigen retrieval solution to retrieve their antigen epitopes, and endogenous peroxidase activity was blocked with 3% H2O2. Tissue sections were incubated overnight at 4°C with primary antibodies, including rabbit polyclonal anti-CD3 (1:200 dilution; ab4055, Abcam, Cambridge, UK) for CD3+ T lymphocytes, mouse monoclonal anti-CD8 (1:300 dilution; clone G10F5, BD Pharmingen, San Diego, CA, USA) for CD8+ T lymphocytes, anti-CD4 (1:300 dilution; clone 1D6, Novocastra, Newcastle, UK) for CD4+ T lymphocytes, and anti-FOXP3 (1:300 dilution; clone 10D6, Novocastra) for FOXP3+ T lymphocytes. The secondary antibody was incubated in a ready-for-use EnVision-peroxidase system (Dako Japan, Tokyo, Japan).
Sections were incubated with horseradish peroxidase-labeled polymer (EnVision1kit, Dako, Carpineteria, CA, USA) for 30 min at 25°C and incubated with 3,3-diaminobenzidine tetrahydrochloride (applied as a 0.02% solution containing 0.005% H₂O₂ in 0.05 M Tris–HCl; pH 7.6) at 25°C for 5–15 min and counterstained with hematoxylin. We counted each positive lymphocyte in the invasive tumor margin using a BZ-X700 digital microscope at a magnification of 200x (Keyence) using hybrid cell count software (BZ-H3C; Keyence; Figure S1).

2.4 Measurement and evaluation of skeletal muscle mass

Skeletal muscle area was measured retrospectively using images from CT performed before surgery at the third lumbar vertebra level in the inferior direction, with the patient in the supine position. We briefly measured the number of pixels using a window width of –30 to 150 HU to delineate muscle compartments and compute their cross-sectional areas in cm² using the Volume Analyzer Synapse Vincent 3D image analysis system (Fujifilm Medical, Tokyo, Japan). The cross-sectional area of the muscle (cm²) at the L3 level computed from each image was normalized by the square of the height (m²) to obtain the skeletal muscle index (SMI; cm²/m²). We divided the patients into quartiles according to the SMI using a sex-specific categorical variable (Q1 [males: 29.3–43.5, n = 26]; Q2 [males: 43.6–50.3, n = 38]; females: 37.3–41.8, n = 27]; Q3 [males: 50.5–56.6, n = 38]; females: 41.9–45.9, n = 26], and Q4 [males: 57.0–85.0, n = 37]; females: 46.0–56.2, n = 26]). We defined the lowest SMI (Q1) as a sarcopenia condition.

2.5 Microsatellite instability analysis

Microsatellite instability (MSI) analysis was performed using the BAT25 and the BAT26 primer set. The sense primers were labeled with FAM. Polymerase chain reaction (PCR) was performed, and dye-labeled PCR products were analyzed with an ABI PRISM 3100 Genetic Analyzer using Genescan 3.7 software (Applied Biosystems, Darmstadt, Germany). A total of 0.5 µL PCR product was mixed with 9.25 µL highly deionized formamide and 0.25 µL DNA Size Standard LIZ 500 (~250; Applied Biosystems). This mixture was denatured for 3 min at 95°C, immediately placed on ice, and separated using an ABI 3130 Genetic Analyzer. Results were analyzed using GeneMapper software (Applied Biosystems). Both tumor and normal tissue samples were analyzed. Samples were divided into two groups: those with one or more of the two markers displaying MSI and those with no instability (microsatellite stable).

2.6 Statistical analysis

C ± standard deviation (SD) or median (interquartile range) was calculated according to the data type (parametric or nonparametric), and differences were assessed for significance using Student’s t-test or the Mann–Whitney test. Categorical variables were evaluated using the chi-squared or Fisher’s exact test, as appropriate. We conducted ordinal logistic regression analysis to assess associations of the density of TILs with SMI (an ordinal outcome variable [Q1 vs Q2 vs Q3 vs Q4]). Cox proportional hazard regression analyses were performed to identify predictors of prognosis. RFS and OS rates were estimated using the Kaplan–Meier method, and survival curves were compared using the log-rank test. Statistical significance was set at P < .05. All tests were performed using JMP software (v. 13.0.0; SAS Institute, Cary, NC, USA) and R (v. 3.4.4; www.r-project.org).

3 RESULTS

3.1 Preoperative SMI and long-term outcomes

We measured the SMI of 256 patients with CRC who underwent primary tumor resection using a preoperative CT scan. Table 1 shows the clinical and pathological features of the 256 cases according to the SMI. The median patient follow-up was 62.5 mo (95% confidence interval [CI]: 51.4–94.1), as measured by the reverse Kaplan–Meier method. Kaplan–Meier curves were constructed to assess the RFS and OS of CRC patients. In this analysis, patients in the lowest skeletal muscle group (ie, Q1 patients) experienced significantly shorter RFS (5-y RFS, Q1 vs Q4 = 41.1% vs 75.3%; log-rank P < .001) and OS (5-y OS, Q1 vs Q4 = 47.1% vs 81.8%; log-rank P < .001) compared with those in the highest skeletal muscle group (Figure 1).

3.2 Preoperative intratumoral TILs and recurrence-free survival

Kaplan–Meier curves were constructed to assess the RFS of CRC patients according to intratumoral TILs. We regarded CD3+, CD8+, CD4+, and FOXP3+ T lymphocytes as local immune status. The local immune cells were evaluated by immunohistochemistry (Figure S1) and are presented in Figure 2, which shows the Kaplan–Meier curves for survival in CRC patients according to TILs. There were recurrences in 47 cases in this study. The recurrence types of CRC were 24 (51.1%) liver metastases, 13 (27.7%) lung metastases, six (12.8%) lymph node metastases, four (8.5%) local recurrences, four (8.5%) peritoneal disseminations, and one (2.1%) ovariectomy (Table 1). There were significant differences between CD8+ lymphocytes and lung recurrence and lymph node recurrence (lung, P = .045; lymph node, P = .050; Table S1). CD4+ and FOXP3+ lymphocytes were significantly lower in patients with lymph node recurrence (CD4, P = .039; FOXP3, P = .027; Table S1). Patients with low expression of TILs showed a significantly shorter RFS except CD4+ TILs (CD3+, P = .005; CD8+, P < .001; CD4+, P = .202; FOXP3+, P = .028).
## 3.3 Relationship between skeletal muscle status and density of TILs

To investigate the impact of skeletal muscle status on local immune systems and cancer progression, we analyzed the relationship between TILs and SMI. In addition, we evaluated the association with clinicopathological factors, such as albumin and CRP (C-reactive protein). It was inferred that they would be related to sarcopenia. In our analysis, SMI was significantly correlated with the number of CD3^+ and CD8^+ cells, as shown in Figure 3. Ordinal logistic regression

### Table 1: Patient characteristics

| Variables                  | All | Q1 | Q2 | Q3 | Q4 | P value |
|----------------------------|-----|----|----|----|----|---------|
| Age, y (range)             | 69  | 70 | 71 | 69 | 68 | .12     |
| Gender                     |     |    |    |    |    |         |
| Male                       | 151 | 38 | 38 | 38 | 37 | 1.00    |
| Female                     | 105 | 26 | 27 | 26 | 26 |         |
| Body mass index, kg/m^2 (range) | 22.0 | 20.0 | 22.0 | 21.8 | 24.4 | <.001  |
| Tumor location             |     |    |    |    |    |         |
| Right-sided                | 75  | 23 | 16 | 22 | 14 | .28     |
| Left-sided                 | 89  | 22 | 24 | 16 | 27 |         |
| Rectum                     | 92  | 19 | 25 | 26 | 22 |         |
| Tumor depth                |     |    |    |    |    |         |
| pT1                        | 24  | 3  | 5  | 8  | 8  | .33     |
| pT2-4                      | 232 | 61 | 60 | 56 | 55 |         |
| Lymph node metastases      |     |    |    |    |    |         |
| Present                    | 104 | 29 | 27 | 27 | 21 | .56     |
| Absent                     | 152 | 35 | 38 | 37 | 42 |         |
| Disease stage (AJCC)       |     |    |    |    |    |         |
| I                          | 68  | 14 | 15 | 20 | 19 | .028    |
| II                         | 72  | 17 | 17 | 17 | 21 |         |
| III                        | 68  | 17 | 13 | 23 | 15 |         |
| IV                         | 48  | 16 | 20 | 4  | 8  | .59     |
| Tumor differentiation      |     |    |    |    |    |         |
| Well to moderate           | 221 | 56 | 57 | 52 | 56 |         |
| Poor                       | 35  | 8  | 12 | 12 | 7  |         |
| Lymphatic invasion         |     |    |    |    |    |         |
| Present                    | 107 | 28 | 28 | 28 | 23 | .80     |
| Absent                     | 149 | 36 | 37 | 36 | 40 |         |
| Venous invasion            |     |    |    |    |    |         |
| Present                    | 137 | 34 | 37 | 30 | 36 | .62     |
| Absent                     | 119 | 30 | 28 | 34 | 27 |         |
| MSI status                 |     |    |    |    |    |         |
| MSS/MSI-Low                | 226 | 58 | 58 | 54 | 56 | .99     |
| MSI-High                   | 30  | 6  | 27 | 26 | 26 |         |

Note: Q1 [male: SMI 29.3–43.5; female: SMI 25.0–37.3], Q2 [male: SMI 43.6–50.3; female: SMI 37.3–41.8], Q3 [male: SMI 50.5–56.6; female: SMI 41.9–45.9], and Q4 [male: SMI 57.0–85.0; female: SMI 46.0–56.2].

Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; MSI, microsatellite instability; MSS, microsatellite-stable; SMI, skeletal muscle index.
analysis showed that CD3⁺ and CD8⁺ cells were independently associated with the SMI in patients with CRC, like other factors such as albumin and CRP (Table 2).

3.4 | Prognostic value of skeletal muscle status and TILs in patients with CRC

Next, we evaluated the prognostic value of the combination of skeletal muscle status and TILs. The patients were divided into four groups according to SMI (SMI-low Q1 vs SMI-high Q2–4) and TIL status (high vs low by median). Patients with SMI-low and CD3-low had a significantly shorter RFS than the other patients (P < .001; Figure 4A). Patients with SMI-low and CD8-high had a favorable prognosis compared with the other patients (P < .001; Figure 4B).

The multivariate Cox regression analyses showed the combination of SMI-low and low-CD3 or CD8 were independent predictors of RFS in CRC patients (SMI/CD3 TILs: hazard ratio [HR] = 2.90, 95% CI = 1.82–4.62, P < .001; SMI/CD8 TILs: HR = 3.01, 95%CI = 1.84–4.90, P < .001; Table 3).

4 | DISCUSSION

This study comprehensively analyzed the relationship between skeletal muscle status and TILs in patients with CRC who underwent curative resection. Cases with a lower SMI and low expression of TILs showed significantly shorter RFS and OS compared with cases with a higher SMI. SMI was significantly correlated with the number of CD3⁺ and CD8⁺ cells in the ordinal logistic regression analysis. To the best of our knowledge, this is the first report showing that CD3⁺ and CD8⁺ lymphocytes correlated with skeletal muscle status and prognosis in patients with CRC. Moreover, patients with low skeletal muscle status and low CD8⁺ cells had an unfavorable prognosis compared with patients with high skeletal muscle status and high CD8⁺ cells.

Although sarcopenia has been associated with morbidity and mortality in previous reports, the mechanisms are not completely understood. Some reports have reported that skeletal muscle and adipose tissues secrete several different cytokines and peptides. 19,20 Thus, these peptides may affect the immune system, especially natural killer cells and innate immune cells, which help to control intracellular infectious agents and cancers. However, there have been
few reports showing this relationship in clinical samples. We comprehensively analyzed systemic immune cells from clinical data and assayed TILs using immunohistochemistry.\textsuperscript{21} There is growing evidence that the local immune response plays an important role in the progression of a variety of solid tumors.\textsuperscript{10,11,14,22} In previous studies, evidence has suggested that TILs may be correlated with improved clinical outcomes in patients with CRC. The prognostic impact of the tumor microenvironment has been clearly established for preneoplastic lesions, primary tumors, and metastasis.\textsuperscript{13,23,24} Consistent with previous reports, this study confirmed the usefulness of CD3\textsuperscript{+} and CD8\textsuperscript{+} T-cell densities as prognostic factors.\textsuperscript{11,23} Importantly, in localized CRC, TILs were found to be more efficient at stratifying patient prognosis and predicting the benefits of adjuvant cytotoxic chemotherapy than TNM staging.\textsuperscript{11,13} In particular, TILs, including CD8\textsuperscript{+} lymphocytes, have been associated with favorable clinical outcomes in multiple tumor types. The present study also revealed that the CD8\textsuperscript{+} lymphocyte count in CRC tissues was associated with patient prognosis. In this study, there were recurrences in 47 cases. Patients with liver recurrence tended to show fewer CD8\textsuperscript{+} lymphocytes (\(P = 0.077\); Table S1). Moreover, CD8\textsuperscript{+} lymphocytes were significantly lower in patients with lung and lymph node recurrences (lung, \(P = 0.045\); lymph node, \(P = 0.050\); Table S1). Thus, some TILs might be associated with recurrence. However, the relationship between TILs and recurrence types is unclear because of the small number of cases.

We also showed that sarcopenia was significantly correlated with the number of CD3\textsuperscript{+} and CD8\textsuperscript{+} cells. Previously, Kitano et al showed that sarcopenia and systemic or local immune cells may interact with each other and play a pivotal role in clinical outcomes for patients with extrahepatic cholangiocarcinoma.\textsuperscript{14} Our results do not demonstrate whether skeletal muscle loss was the cause or the result of local immunity suppression. In vitro experiments are needed to show this mechanism. However, Chatraw et al\textsuperscript{21} reported that protein energy malnutrition (PEM) led to lower numbers of CD8\textsuperscript{+} lymphocytes and increased the incidence and severity of infection in mice. As a result, PEM-induced muscle loss might decrease immune activity. We support this mechanism and believe that skeletal muscle loss is the cause of suppression of local immunity.\textsuperscript{21} Furthermore, Rundqvist et al reported CD8\textsuperscript{+} T cells are metabolically enhanced by exercise in mice.\textsuperscript{25} This exercise-induced reduction in tumor growth was dependent on CD8\textsuperscript{+} T cells. Both of these reports were from mouse models, but they support our mechanism. Therefore, in patients with malnutrition, decreased antigen-presenting ability, and decreased interleukin (IL)-2 and interferon (IFN)-\(\gamma\) production may be observed, leading to decreased activation and migration CD8\textsuperscript{+} lymphocytes. Moreover, SMI was significantly correlated with the number of CD3\textsuperscript{+} and CD8\textsuperscript{+} cells in our study. Lutz and Quinn revealed that IL-15 was highly expressed in skeletal muscle tissue and declined in aging rodent models, and that IL-15 was required to develop and maintain natural killer lymphocytes.\textsuperscript{26} They suggested that decreased IL-15 levels during aging constitute a common mechanism for sarcopenia and immune senescence. Another study reported that immune senescence resulted from an imbalance in inflammatory and anti-inflammatory mechanisms, and cancer, as well
as aging, was one such condition. In such inflammatory conditions, the proinflammatory cytokine IL-6 is elevated, leading to one of the essential components of sarcopenia.

In this study, patients with low skeletal muscle status and low CD8\(^+\) cells showed an unfavorable prognosis compared with patients with high CD8\(^+\) cells. This result shows that low expression of TILs may contribute to poor prognosis in patients with CRC.

Accumulating evidence demonstrates a significant role of tumor microenvironment cells in both cancer progression and tumor-induced muscle loss via the production of multiple inflammatory factors. However, the mechanisms of intratumoral CD8\(^+\) cells in sarcopenia, and how they might affect prognosis, remain unclear. Our data may provide new ideas for the exploration of potential mechanisms.

Recently, several studies showed a relationship between systemic inflammation and local immune systems, such as TILs or tumor-associated macrophages, in patients with gastrointestinal cancers. Okadome et al hypothesized that there was a relationship between nutritional status and local immune competence with Prognostic Nutritional Index (PNI) and immunobiological features in patients with esophageal cancer.

Associations between systemic and local immune responses should be analyzed to better understand the tumor microenvironment in CRC patients.

This study had some limitations. First, our dataset was obtained from a single institution and was collected retrospectively. Second, our study only included preoperative SMI status and did not consider the postoperative host status for prognosis. Fourth, there were significant differences between SMI and pathological stage (Table 1, \(P = .028\)). These differences might affect the present study results. Actually, these differences might affect the prognosis of CRC patients according to SMI. However, we included several

### TABLE 2 Ordinal logistic regression analysis to assess independent associations of tumor-infiltrating lymphocytes with the skeletal muscle index

| | Univariate analysis | Multivariate analysis\(^a\) |
|---|---|---|
| | OR (95\% CI) | \(P\) value | OR (95\% CI) | \(P\) value |
| Albumin (g/dl) | 6.35 (1.64–2.50) | .001 | 4.91 (1.45–2.53) | .001 |
| CRP (mg/dl) | 1.73 (1.02–1.28) | .019 | 1.61 (1.17–1.28) | .026 |
| WBC (/\(\mu\)l) | 0.30 (0.60–1.22) | .496 | 0.18 (0.72–1.13) | .662 |
| Neutrophil (%) | 2.43 (1.09–1.49) | .004 | 1.51 (1.21–1.43) | .031 |
| Monocyte (%) | 0.82 (0.72–1.19) | .152 | 0.52 (0.51–1.71) | .304 |
| Lymphocyte (%) | 2.89 (1.60–2.14) | .001 | 1.97 (1.55–1.72) | .011 |
| NLR | 2.71 (1.53–2.48) | .002 | 1.95 (1.28–2.27) | .011 |
| Vascular emboli | 0.02 (0.77–1.21) | .952 | 0.99 (0.55–1.42) | .103 |
| Lymphatic invasion | 0.35 (0.86–1.31) | .451 | 0.17 (0.47–1.34) | .678 |
| CD3 (for 10 increase) | 1.17 (1.05–1.31) | .005 | 1.18 (1.05–1.32) | .006 |
| CD8 (for 10 increase) | 1.17 (1.04–1.33) | .011 | 1.16 (1.01–1.33) | .037 |
| CD4 (for 10 increase) | 0.90 (0.78–1.05) | .186 | 0.87 (0.74–1.01) | .075 |
| Foxp3 (for 10 increase) | 1.11 (0.98–1.27) | .111 | 1.08 (0.94–1.24) | .263 |

Abbreviations: CEA, carcinoembryonic antigen; CI, confidence interval; CRP, C reactive protein; MSI, microsatellite instability; MSI-H, microsatellite instability-high; MSS, microsatellite-stable; NLR, neutrophil/lymphocyte ratio; OR, odds ratio; WBC, white blood cell.

\(^a\)Multivariate ordinal logistic regression analysis model included age (continuous), sex (male vs female), location (right vs left vs rectum), differentiation (well, moderate vs poor), Stage (I vs II vs III vs IV), MSI (MSS vs MSI-H), CEA (high vs normal). Bold type indicates values significant at \(P < .05\).
clinical and pathological factors in ordinal logistic regression analysis and multivariate Cox regression analysis. Therefore, we thought these influences were minimal. In this study, although we revealed that sarcopenia is associated with the immune system in CRC patients, it remains unclear whether sarcopenia is a cause or result of the immune system findings, or whether another confounding factor exists. Therefore, further analyses, such as in vivo analyses, are required. Nevertheless, this was the first study to investigate the relationship between SMI and TILs in patients undergoing curative surgery for CRC.

In conclusion, the relationship between skeletal muscle status and TILs may play a pivotal role in the clinical outcomes of patients with CRC who have undergone curative resection. These mechanisms may be exploited in cancer therapeutics, such as immune therapy or preoperative nutritional intervention. Future studies are needed to confirm our findings and examine other potential mechanisms by which skeletal muscle status affects TILs.

ACKNOWLEDGMENTS
We thank Georgia Lenihan-Geels, PhD, and H. Nikki March, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this article.

DISCLOSURE
Funding: No funding source.
Conflicts of Interest: Author Hideo Baba is an editorial board member of Annals of Gastroenterological Surgery. The funding source had no role in the design, practice, or analysis of this study.

Presentation: We have not submitted this article elsewhere.
Ethical Approval: Institutional Review Board of Kumamoto University (number 1047).
Informed Consent: Consent was obtained from the patients and families according to Institutional Review Board protocols.

ORCID
Yuji Miyamoto https://orcid.org/0000-0003-3948-5044
Yukiharu Hiyoshi https://orcid.org/0000-0002-9209-554X
Yoshifumi Baba https://orcid.org/0000-0003-3657-2388
Naoya Yoshida https://orcid.org/0000-0002-8447-5278
Hideo Baba https://orcid.org/0000-0002-3474-2550

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. van der Stok EP, Spaander MCW, Grünhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol. 2017;14(5):297–315.
3. Tokunaga R, Sakamoto Y, Nakagawa S, Miyamoto Y, Yoshida N, Oki E, et al. Prognostic nutritional index predicts severe complications, recurrence, and poor prognosis in patients with colorectal cancer undergoing primary tumor resection. Dis Colon Rectum. 2015;58(11):1048–57.
4. Daitoku N, Miyamoto Y, Tokunaga R, Sakamoto Y, Hiyoshi Y, Iwatsuki M, et al. Controlling Nutritional Status (CONUT) score is a prognostic marker in metastatic colorectal cancer patients receiving first-line chemotherapy. Anticancer Res. 2018;38(8):4883–8.
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.

6. Harada K, Ida S, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, et al. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. Dis Esophagus. 2016;29(6):627–33.

7. Matsunaga T, Miyata H, Sugimura K, Motoori M, Asukai K, Yanagimoto Y, et al. Prognostic significance of sarcopenia and systemic inflammatory response in patients with esophageal cancer. Anticancer Res. 2019;39(1):449–58.

8. Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol. 2015;22(8):2663–8.

9. Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, et al. Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS One. 2015;10(6):e0129742.

10. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–66.

11. Pagès F, Mlecink B, Marliot F, Bindea G, Ou F-S, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–39.

12. Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C, et al. The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):3360.

13. Mlecink B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, et al. Multicenter International Society for Immunotherapy of Cancer Study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol. 2020;38(31):3638–51.

14. Kitano Y, Yamashita Y-I, Saito Y, Nakagawa S, Okabe H, Imai K, et al. Sarcopenia affects systemic and local immune system and impacts postoperative outcome in patients with extrahepatic cholangiocarcinoma. World J Surg. 2019;43(9):2271–80.

15. Sauerbrei W, Taube SE, McShane LM, Cavanagh MM, Altman DG, et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst. 2018;110(8):803–11.

16. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.

17. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.

18. Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, et al. Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. Br J Cancer. 2013;109(2):408–15.

19. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–65.

20. Trayhurn P, Drevon CA, Eckel J. Secreted proteins from adipose tissue and skeletal muscle - adipokines, myokines and adipose/muscle cross-talk. Arch Physiol Biochem. 2011;117(2):47–56.

21. Chatraw JH, Wherry EJ, Ahmed R, Kapasi ZF, et al. Diminished primary CD8 T cell response to viral infection during protein energy malnutrition in mice is due to changes in microenvironment and low numbers of viral-specific CD8 T cell precursors. J Nutr. 2008;138(4):806–12.

22. Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, lwatsuki M, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surg. 2020;271(4):693–700.

23. Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, et al. Intratumoural-infiltrating CD4+ and FOXP3+ T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. Br J Cancer. 2019;121(8):659–65.

24. Choi Y, Kim JW, Nam KH, Han S-H, Kim J-W, Ahn S-H, et al. Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer. 2017;20(4):602–11.

25. Rundqvist H, Veliça P, Barbieri L, Gameiro PA, Bargiela D, Gojkovic M, et al. Cytotoxic T-cells mediate exercise-induced reductions in tumor growth. eLife. 2020;9:e59996.

26. Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging. 2012;4(8):535–46.

27. Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence. eBioMedicine. 2019;49:381–8.

28. Kasprzak A. The role of tumor microenvironment cells in Colorectal Cancer (CRC) Cachexia. Int J Mol Sci. 2021;22(4):1565.

29. Mano Y, Yoshizumi T, Yugawa K, Ohira M, Motomura T, Toshima T, et al. Lymphocyte-to-monocyte ratio is a predictor of survival after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2018;24(11):1603–11.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.